Recent Updates
Recently added Catalysts

Ezogabine/retigabine

Phase 1

Epilepsy | Small molecule | Neurology |GSK plc|Last Updated: Jun 19, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDBiomarker
Total Trials1
Total Enrollment1
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01462669Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Taiwanese SubjectsPHASE1 COMPLETED 1Apr 10, 2012Jun 27, 2012Jun 19, 20181 Taiwan
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Pharmacokinetics of single oral doses of ezogabine/retigabine and NAMR over the range of 50mg to 400mg in healthy male and female Taiwanese volunteers
Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 14 weeks

Peak plasma concentration (Cmax) of ezogabine/retigabine; and area under the plasma concentration-time curve from time zero to infinity (AUC(0-∞)) for ezogabine/retigabine

Secondary Endpoints
Pharmacokinetics of single oral doses of ezogabine/retigabine and NAMR over the range of 50mg to 400mg in healthy male and female Taiwanese volunteers
Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 14 weeks
Safety and tolerability data after single oral doses of ezogabine/retigabine in healthy male and female Taiwanese volunteers
Participants will be followed and monitored for the duration of their hospital stay. The longest duration of participation in the study will be approximately 14 weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Treatment Period 1OTHERA single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
Treatment Period 2OTHERA single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
Treatment Period 3OTHERA single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
Treatment Period 4OTHERA single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
Interventions
NameTypeDescription
50mg Ezogabine/retigabineDRUGA single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
100mg Ezogabine/retigabineDRUGA single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
200mg Ezogabine/retigabineDRUGA single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
400mg Ezogabine/retigabineDRUGA single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
Unlock Study Design Details
Eligibility Criteria
Age Range20 Years — 65 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: A subject will be eligible for inclusion in this study only if all of the following criteria apply: 1. Male or female between 20 and 65 years of age inclusive, at the time of signing the informed consent. 2. Taiwanese ancestry defined as being born in Taiwan, having four ethnic...

Countries:Taiwan
Unlock Eligibility Criteria